The Silent Role of Biofilms in Chronic Disease › Forums › Biofilm Community › The Standard of Care › Hospital-acquired Infections, VAP and Biofilm Awareness › Reply To: Hospital-acquired Infections, VAP and Biofilm Awareness
I found the time to locate the Russian article and it provides some interesting insights into this topic.
Here is an excerpt:
“...The limitations of routine susceptibility tests were also included in Mark Wilcoxs presentation on coagulase-negative staphylococcal infections, where planktonic organisms in biofilms can compromise the reliability of in vitro tests. In similar vein, Andrei Dekhnich, in a wide-ranging review of chronic infections, noted the potential for b-lactamases to accumulate in biofilms and so inhibit antibiotic activity...”
Also, this closing excerpt suggests the importance of using molecular diagnostics, then immediately prescribing the correct antidote:
“…The importance of using current agents effectively in critical care patients was reviewed by Robert Masterton, who stressed how increased doses and infusion times in serious Gram-negative infections could minimize resistance as well as improve clinical responses…”
To not do both (diagnose and treat properly), the clinician sets up the patient for further infection, suffering and disease.
The PDF is attached.
J. Antimicrob. Chemother.-2007-Davey-1193-4.pdf